Disease landscape

Multiple Sclerosis clinical trials

Get alerts when Multiple Sclerosis trials change

734 active trials 372 recruiting 54 Phase 3 388 sponsors 83 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 42 of 83 changes on 20 trials

2026-08-08
Trial status changed: Completed → Terminated
Trial terminated: The study was terminated early due to NIH funding withdrawal before reaching the planned sample size of 50 participants...
NCT05998616 Feasibility of Remote Exercise Training for Hispanics/Latinos With MS · University of Illinois at Chicago
2026-08-20
Primary completion pushed: 2026-02-28 → 2026-05-30
Trial completed
Completion pushed: 2026-02-28 → 2026-05-30
NCT04091464 TRAIN-BW: Backward Walking Training in Multiple Sclerosis · Wayne State University
2026-08-15
Primary completion pushed: 2026-06-29 → 2027-06-29
NCT05958381 Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial… · The University of Texas at Dallas
2026-08-13
Primary completion pushed: 2026-04-14 → 2027-04-14
Completion pushed: 2026-04-14 → 2027-04-14
NCT07111637 Artificial Intelligence-Assisted Magnetic Resonance Imaging for Quality, Efficiency and… · Queen Mary University of London
2026-08-12
Primary completion pushed: 2025-10-31 → 2026-04-17
Enrollment reduced: 120 → 76 participants
Completed without a posted recruiting period
Completion pushed: 2025-12-31 → 2026-04-17
NCT07063810 NEO-REEDUC - Mixed Reality for Motor Rehabilitation: a Prospective, Multicenter… · Slb Pharma
2026-08-12
Primary completion pushed: 2026-05-01 → 2026-09-01
Completion pushed: 2026-05-01 → 2026-09-01
NCT05837949 Multiple Sclerosis Falls Insight Track · University of California, San Francisco
2026-08-06
Primary completion pushed: 2026-06-30 → 2027-09-30
Completion pushed: 2026-06-30 → 2027-09-30
NCT06197685 A Novel Combinatory Approach to Maximize Functional Recovery of Learning and Memory in… · Kessler Foundation
2026-08-14
Primary endpoint(s) modified
Trial arms changed: 3 → 4
NCT05704361 A Study to Investigate the Safety, Tolerability, and Processing by the Body of… · Hoffmann-La Roche · Phase 1
2026-08-06
Primary endpoint(s) modified
Enrollment reduced: 44 → 38 participants
Completed without a posted recruiting period
NCT07390201 Effect of Sensory Integration Therapy on Gait Variability and Quality Of Life in Patients… · Cairo University
2026-08-27
Enrollment reduced: 14 → 10 participants
Trial completed
NCT07663266 Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury · University of Michigan
2026-08-08
Enrollment reduced: 30 → 21 participants
Trial completed
NCT03969927 User-friendliness of a Portable Driving Simulator · University of Kansas Medical Center
2026-08-07
Enrollment closed, study ongoing
Trial sites reduced: 56 → 50 locations
Primary completion moved earlier: 2027-01-31 → 2026-09-17
Completion moved earlier: 2030-10-30 → 2030-03-31
NCT07074886 A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in… · Hoffmann-La Roche · Phase 2
2026-07-30
Recruitment opened
NCT07609719 A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple… · Genentech, Inc. · Phase 4
2026-08-14
Enrollment closed, study ongoing
NCT07667322 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and… · Hoffmann-La Roche · Phase 1
2026-08-04
Enrollment closed, study ongoing
NCT06220201 A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in… · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Phase 1
2026-08-22
Primary completion pushed: 2027-05-30 → 2027-07-31
NCT07503873 A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab… · TG Therapeutics, Inc. · Phase 2
2026-08-04
Enrollment closed, study ongoing
Primary completion pushed: 2026-08-12 → 2026-09-17
Completion pushed: 2026-08-12 → 2026-09-17
NCT07550699 Clinical Investigation to Validate the Safety and Performance of Integrating Functional… · ABLE Human Motion S.L.
2026-08-27
Enrollment increased: 360 → 400 participants
NCT06846281 Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants… · Novartis Pharmaceuticals · Phase 3
2026-08-14
Completed without a posted recruiting period
Enrollment increased: 10 → 11 participants
Primary completion moved earlier: 2026-09-10 → 2026-08-11
Completion moved earlier: 2027-12-31 → 2026-08-11
NCT07687693 Simultaneous T2-FLAIR and T1 Brain MRI With ENRAGED FLAIR in Multiple Sclerosis · Region Stockholm
2026-08-18
Recruitment opened
NCT07759115 Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility… · University of Texas at Austin

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-26 NCT07788573 The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response… Université Catholique de Louvain new
2026-08-26 NCT07786506 Intermittent Theta-Burst Stimulation for Lower-Limb Spasticity and Pain in Multiple… Comenius University new
2026-08-24 NCT07783269 A Basket Study of CTA313 in Participants With Active Autoimmune Diseases Imviva Bio new Phase 1
2026-08-24 NCT07783074 Fatigue Investigation Using Digital Outcomes Liliana Barrios new
2026-08-20 NCT07776743 A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis Guangzhou Lupeng Pharmaceutical Company LTD. new Phase 2
2026-08-17 NCT07769294 PLasmatic Extracellular Vesicles AS Biomarkers of nEural Tissue Damage Roberto Furlan new
2026-08-14 NCT07765212 Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive… Eva M.M. Strijbis new Phase 2
2026-08-10 NCT07753928 MS-Related Disability Worsening and Thalamic Volume Loss Jung Diagnostics GmbH new
2026-08-03 NCT07741864 Effectiveness of a Mindfulness-Based Intervention for Pain Management in Patients With… Hospital Universitario Virgen Macarena new
2026-07-31 NCT07738978 Understanding and Enhancing Human Health and Movement Louis Stokes VA Medical Center new

Active trials by phase

Early Phase 1
17
Phase 1
42
Phase 1/2
17
Phase 2
53
Phase 2/3
4
Phase 3
50
Phase 4
25
Not charted: 526 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 734

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT07609719 A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple… Genentech, Inc. Recruiting 2026-08-13
NCT05285891 Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis National Institute of Allergy and Infectious Diseases (NIAID) Recruiting 2026-08-10
NCT04480853 Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing… Novartis Pharmaceuticals Recruiting 2026-06-26
NCT07614321 Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis Atlantic Health System Recruiting 2026-05-29
NCT06733922 ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS Novartis Pharmaceuticals Recruiting 2026-05-15
NCT07389590 Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis Johns Hopkins University Recruiting 2026-05-06
NCT07225361 Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis Northwestern University Recruiting 2026-03-17
NCT07087106 Glucose Consumption in MS Using [F-18]FDG-PET Brigham and Women's Hospital Recruiting 2026-01-09
NCT07303582 Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and… Oxford University Hospitals NHS Trust Recruiting 2025-12-26
NCT06529406 Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod University of Colorado, Denver Recruiting 2025-09-18
NCT04650321 Home Based Infusions for Ocrelizumab University of Colorado, Denver Recruiting 2021-06-10
NCT06444113 Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of… Novartis Pharmaceuticals Active, Not Recruiting 2026-08-12
NCT07240649 Emerging Indications for Hyperbaric Oxygen Treatment Jay C. Buckey Jr. Not Yet Recruiting 2026-07-06
NCT07483450 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of… Hoffmann-La Roche Active, Not Recruiting 2026-07-06
NCT04387734 Effects of Ocrevus in Relapsing Multiple Sclerosis Georgia State University Active, Not Recruiting 2026-06-17
NCT05296161 B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple… Amsterdam UMC, location VUmc Active, Not Recruiting 2026-06-10
NCT05090371 A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After… Novartis Pharmaceuticals Active, Not Recruiting 2026-05-29
NCT06495593 Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis University of California, San Francisco Enrolling by Invitation 2026-03-27
NCT04466150 Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset University of California, San Francisco Active, Not Recruiting 2026-01-26
NCT04178005 Cladribine Tablets After Treatment With Natalizumab (CLADRINA) University of Texas Southwestern Medical Center Active, Not Recruiting 2025-12-08
NCT04601233 Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis Tulane University Not Yet Recruiting 2025-08-29
NCT03535298 Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS The Cleveland Clinic Active, Not Recruiting 2025-08-28
NCT02670161 Quality Improvement and Practice Based Research in Neurology Using the EMR Endeavor Health Enrolling by Invitation 2025-08-24
NCT07138833 A Phase IV Study of Dimethyl Fumarate Enteric-coated Capsules for Relapsing Multiple… Qilu Pharmaceutical (Hainan) Co., Ltd. Not Yet Recruiting 2025-08-24
NCT06396039 A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With… Bristol-Myers Squibb Active, Not Recruiting 2025-04-16
See all 734 active Multiple Sclerosis trials with filters →

Top sponsors by active trials in this area

Novartis Pharmaceuticals (25) · Hoffmann-La Roche (21) · University of California, San Francisco (10) · University of Illinois at Chicago (9) · TG Therapeutics, Inc. (8) · Assiut University (7) · Bristol-Myers Squibb (7) · Cairo University (7) · Shirley Ryan AbilityLab (7) · Tongji Hospital (7)

Get alerts when Multiple Sclerosis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free